Follow-up: Reading an interaction checker output critically

Following this. I have the same question and no better information than the first post.

Reading an interaction checker output sits at the boundary between what this community can usefully discuss and what it cannot, and I think it falls on the discussable side, narrowly.

Answering the question post #23 raises rather than the one it answers.

Insulin and sulfonylureas are the interaction that the labelling in this class flags most explicitly, because the risk is additive glucose lowering. That is a prescribing question and not a forum question.

Not disagreeing with anyone above, just adding the bit I keep having to look up.

Separation timing versus clinically important interaction: a separation timing inconvenience (taking one medication 2 hours before or after another) is not the same as a clinically important interaction. Both can reduce absorption of one or the other, but only true interactions require active management.

Post #34 is the version of this I will quote in future. One addition.

Renal or hepatic impairment changes the calculus for a lot of combinations and is the context most often missing from an interaction question here.

Happy to expand any of that if it is the useful part.

Research-use-only compounds have no interaction data of any kind, because interaction studies are done on medicines being developed for use in people.

I would not lead a decision with this, but I would not ignore it either.

Supplements and herbs: many have no established interaction. Some do. If you are taking something unusual, checking a reference (like a pharmacist) is more useful than guessing from forum discussion.

Gastrointestinal symptoms from one compound can mask or mimic an interaction with another. Introducing two changes at once makes attribution impossible, which is an argument for spacing them.